News from the
peptide desk.
Regulatory changes, research summaries, and market context for peptide therapy — tightened into an editorial feed instead of a dense archive wall.
Semaglutide vs Tirzepatide: A Head-to-Head Evidence Review
Two GLP-1 medications dominate the weight-loss conversation. We compare semaglutide and tirzepatide on mechanism, trial results, side effects, and who each one suits best.
Read the analysisRecent reporting.
Shorter summaries and a cleaner metadata row to make the archive easy to scan.
GLP-1 Peptides for Weight Loss: What the Evidence Actually Shows
GLP-1 receptor agonists changed obesity medicine. Here's an evidence-based review of how they work, what the landmark trials found, and how much weight loss is realistic.
How to Read a Peptide Certificate of Analysis (COA)
A certificate of analysis is a supplier's strongest quality document — or its weakest link. Here's how to read a peptide COA, what each test means, and the red flags to avoid.
Are Peptides Legal in the US? The 2025 Regulatory Status Explained
Peptide legality is not a yes-or-no answer. It depends on FDA approval, compounding rules, and research-chemical status. Here's a clear map of where each category stands in 2025.
Semaglutide Shortage Ends: What It Means for Compounded GLP-1 Access
The FDA declared the semaglutide shortage resolved in early 2025, triggering enforcement action against compounding pharmacies. Here's what changed and what patients should know.
BPC-157 in 2025: What the FDA Prohibition Means and What Remains
The 2023 FDA prohibition of BPC-157 from 503A compounding changed the landscape for one of the most popular research peptides. Here's an honest assessment of where things stand.
Keep exploring
If the blog surfaces a topic you want to understand in more depth, jump into the structured reference pages.